These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37182893)

  • 21. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
    Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
    J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a Clinical Global Impression of Change (CGI-C) and a Caregiver Global Impression of Change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy.
    Staunton H; Trennery C; Arbuckle R; Guridi M; Zhuravleva E; Furlong P; Fischer R; Hall R
    Health Qual Life Outcomes; 2021 Jul; 19(1):184. PubMed ID: 34311756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective Analysis of Fractures and Factors Causing Ambulation Loss After Lower Limb Fractures in Duchenne Muscular Dystrophy.
    Yildiz S; Glanzman AM; Estilow T; Flickinger J; Brandsema JF; Tennekoon G; Banwell BL; Yum S
    Am J Phys Med Rehabil; 2020 Sep; 99(9):789-794. PubMed ID: 32195737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment.
    Merlini L; Cecconi I; Parmeggiani A; Cordelli DM; Dormi A
    Acta Myol; 2020 Dec; 39(4):200-206. PubMed ID: 33458575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management.
    Moxley RT; Pandya S; Ciafaloni E; Fox DJ; Campbell K
    J Child Neurol; 2010 Sep; 25(9):1116-29. PubMed ID: 20581335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model.
    Williams K; Davidson I; Rance M; Boehnke A; Buesch K; Acaster S
    J Patient Rep Outcomes; 2021 Aug; 5(1):75. PubMed ID: 34420127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of budesonide inhalation suspension compared with cromolyn sodium nebulizer solution on health status and caregiver quality of life in childhood asthma.
    Murphy KR; Fitzpatrick S; Cruz-Rivera M; Miller CJ; Parasuraman B
    Pediatrics; 2003 Sep; 112(3 Pt 1):e212-9. PubMed ID: 12949315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study.
    Coates E; Wickramasekera N; Barr A; Shackley P; Lee M; Hind D; Probert C; Sebastian S; Totton N; Blackwell S; Bedford H; Dames N; Lobo A
    Health Technol Assess; 2022 Oct; 26(41):1-118. PubMed ID: 36305390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 30. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
    Merlini L; Gennari M; Malaspina E; Cecconi I; Armaroli A; Gnudi S; Talim B; Ferlini A; Cicognani A; Franzoni E
    Muscle Nerve; 2012 Jun; 45(6):796-802. PubMed ID: 22581531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.
    Matthews DJ; James KA; Miller LA; Pandya S; Campbell KA; Ciafaloni E; Mathews KD; Miller TM; Cunniff C; Meaney FJ; Druschel CM; Romitti PA; Fox DJ;
    J Child Neurol; 2010 Nov; 25(11):1319-24. PubMed ID: 20207610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European Cross-Sectional Survey of Current Care Practices for Duchenne Muscular Dystrophy Reveals Regional and Age-Dependent Differences.
    Vry J; Gramsch K; Rodger S; Thompson R; Steffensen BF; Rahbek J; Doerken S; Tassoni A; Beytía ML; Guergueltcheva V; Chamova T; Tournev I; Kostera-Pruszczyk A; Kaminska A; Lusakowska A; Mrazova L; Pavlovska L; Strenkova J; Vondráček P; Garami M; Karcagi V; Herczegfalvi Á; Bushby K; Lochmüller H; Kirschner J
    J Neuromuscul Dis; 2016 Nov; 3(4):517-527. PubMed ID: 27911335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
    Kourakis S; Timpani CA; Campelj DG; Hafner P; Gueven N; Fischer D; Rybalka E
    Orphanet J Rare Dis; 2021 Mar; 16(1):117. PubMed ID: 33663533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unmet Therapeutic Needs of Non-Ambulatory Patients with Duchenne Muscular Dystrophy: A Mixed-Method Analysis.
    Schuster ALR; Crossnohere NL; Fischer R; Furlong P; Bridges JFP
    Ther Innov Regul Sci; 2022 Jul; 56(4):572-586. PubMed ID: 35325439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychometric properties of the Zarit Caregiver Burden Interview administered to caregivers to patients with Duchenne muscular dystrophy: a Rasch analysis.
    Landfeldt E; Mayhew A; Straub V; Bushby K; Lochmüller H; Lindgren P
    Disabil Rehabil; 2019 Apr; 41(8):966-973. PubMed ID: 29254382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring Duchenne muscular dystrophy impact: development of a proxy-reported measure derived from PROMIS item banks.
    Schwartz CE; Stark RB; Cella D; Borowiec K; Gooch KL; Audhya IF
    Orphanet J Rare Dis; 2021 Nov; 16(1):487. PubMed ID: 34809687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials.
    Schreiber A; Brochard S; Rippert P; Fontaine-Carbonnel S; Payan C; Poirot I; Hamroun D; Vuillerot C;
    Dev Med Child Neurol; 2018 Feb; 60(2):185-191. PubMed ID: 28990163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.